Catalyst Biosciences And GNI Group Sign Agreements Fro Sale And Purchase Of F351 Program; Announces $7.5M Special Divided And Contingent Value Right
Acquires F351, a Phase 3 Drug to Treat Fibrosis
Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction
Announces $7.5